[Advances in molecular mechanism of vascular remodeling in pulmonary arterial hypertension]
- PMID: 31102364
- PMCID: PMC10412420
- DOI: 10.3785/j.issn.1008-9292.2019.02.15
[Advances in molecular mechanism of vascular remodeling in pulmonary arterial hypertension]
Abstract
Pulmonary arterial hypertension (PAH) is a clinical hemodynamic syndrome characterized by elevated pulmonary arterial pressure and pulmonary vascular resistance leading to right heart failure and death. Vascular remodeling is the most prominent histopathological feature of PAH, which is regulated by many factors. Endoplasmic reticulum stress, calcium disorder and mitochondrial dysfunction are involved in the vascular cell proliferation and apoptosis by regulating intracellular calcium homeostasis and cellular metabolism. Epigenetic phenomenon such as DNA damage and abnormal expression of miRNA are also involved in the regulation of abnormal proliferation of vascular cells. Vascular cell phenotype switching including endothelial-mesenchymal transition and smooth muscle cell phenotype switching play an important role in abnormal proliferation of vascular cells. Vascular remodeling is produced by a variety of cells and molecular pathways, and aiming at multiple targets which is expected to find a new breakthrough in the treatment of PAH,and to improve abnormal vascular remodeling, delay or even reverse the progression of PAH.
肺动脉高压(PAH)是以肺动脉压和肺血管阻力升高为特征的临床血流动力学症候群,可导致右心衰竭和死亡。血管重构是PAH最显著的组织病理学特征,其形成受多方面因素的调控。内质网应激、钙紊乱和线粒体功能紊乱通过调节细胞内钙稳态和细胞代谢调控血管细胞的增殖凋亡能力;表观遗传学现象(如DNA损伤和微小RNA表达异常)参与调控血管细胞的异常增殖;血管细胞表型转化(包括内皮细胞间质转化和平滑肌细胞表型转换)是引起血管细胞异常增殖的重要原因。血管重构由多种细胞和分子通路共同作用产生,针对多靶点来改善PAH中发生的异常血管重构,进而延缓甚至逆转PAH的进程,有望成为PAH治疗上新的突破口。
Similar articles
-
Molecular Mechanisms of Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension.Int J Mol Sci. 2016 May 18;17(5):761. doi: 10.3390/ijms17050761. Int J Mol Sci. 2016. PMID: 27213345 Free PMC article. Review.
-
LncRNA-SMILR modulates RhoA/ROCK signaling by targeting miR-141 to regulate vascular remodeling in pulmonary arterial hypertension.Am J Physiol Heart Circ Physiol. 2020 Aug 1;319(2):H377-H391. doi: 10.1152/ajpheart.00717.2019. Epub 2020 Jun 19. Am J Physiol Heart Circ Physiol. 2020. PMID: 32559140
-
Implication of Inflammation and Epigenetic Readers in Coronary Artery Remodeling in Patients With Pulmonary Arterial Hypertension.Arterioscler Thromb Vasc Biol. 2017 Aug;37(8):1513-1523. doi: 10.1161/ATVBAHA.117.309156. Epub 2017 May 4. Arterioscler Thromb Vasc Biol. 2017. PMID: 28473439
-
Targeting Vascular Remodeling to Treat Pulmonary Arterial Hypertension.Trends Mol Med. 2017 Jan;23(1):31-45. doi: 10.1016/j.molmed.2016.11.005. Epub 2016 Dec 16. Trends Mol Med. 2017. PMID: 27989641 Review.
-
Let-7a-transfected mesenchymal stem cells ameliorate monocrotaline-induced pulmonary hypertension by suppressing pulmonary artery smooth muscle cell growth through STAT3-BMPR2 signaling.Stem Cell Res Ther. 2017 Feb 10;8(1):34. doi: 10.1186/s13287-017-0480-y. Stem Cell Res Ther. 2017. PMID: 28187784 Free PMC article.
Cited by
-
Study on the Regulatory Mechanism of the PDK1-Mediated TGF-β/Smad Signaling Pathway in Hypoxia-Induced Yak Lungs.Animals (Basel). 2024 Aug 21;14(16):2422. doi: 10.3390/ani14162422. Animals (Basel). 2024. PMID: 39199957 Free PMC article.
-
Clinical effect and changes of ET-1, FMD and NO levels in the treatment of acute cerebral infarction with acanthopanax injection.Am J Transl Res. 2021 Apr 15;13(4):3600-3608. eCollection 2021. Am J Transl Res. 2021. PMID: 34017541 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical